ArriVent BioPharma, Inc. Common Stock logo AVBP - ArriVent BioPharma, Inc. Common Stock

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 6
HOLD 0
SELL 0
STRONG
SELL
0
| PRICE TARGET: $44.00 DETAILS
HIGH: $45.00
LOW: $43.00
MEDIAN: $44.00
CONSENSUS: $44.00
UPSIDE: 64.61%
Metric 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1 2024 Q4 2024 Q3 2024 Q2 2024 Q1 2023 Q4 2023 Q3 2023 Q2 2023 Q1 2022 Q4 2022 Q3 2022 Q2 2022 Q1
Revenue
Revenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Cost of Revenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Gross Profit 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Operating Expenses
R&D Expenses 37.6 32.2 32.2 27.7 61.3 20.2 20.1 21.8 17.0 20.0 14.3 20.4 10.2 8.6 10.1 5.8 5.8
SG&A Expenses 8.5 6.6 6.1 5.9 5.5 3.5 4.1 3.9 3.7 3.1 2.4 2.2 1.9 1.8 1.7 1.5 1.5
Other Expenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Operating Expenses 46.1 38.8 38.3 33.6 66.8 23.7 24.2 25.7 20.7 23.1 16.7 22.6 12.2 10.4 11.8 7.3 7.3
Operating Income
Operating Income (46.1) (38.8) (38.3) (33.6) (66.8) (23.7) (24.2) (25.7) (20.7) (23.1) (16.7) (22.6) (12.2) (10.4) (11.8) (7.3) (7.3)
Interest Expense 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Interest Income 2.8 3.3 3.3 2.2 2.4 3.1 3.7 3.8 3.3 1.9 2.3 1.0 0 0 0 0 0
Profitability
EBITDA (46.1) (38.8) (35.0) (31.4) (66.8) (23.7) (24.2) (25.7) (20.7) (23.1) (16.7) (22.6) 0 0 0 0 0
EBIT (46.1) (38.8) (35.0) (31.4) (66.8) (23.7) (24.2) (25.7) (20.7) (23.1) (16.7) (22.6) (12.2) (10.4) (11.8) (7.3) (7.3)
Income Before Tax (43.3) (35.5) (35.0) (31.4) (64.4) (20.6) (20.6) (21.9) (17.4) (21.2) (14.4) (21.6) (12.2) (10.4) (11.8) (7.3) (7.3)
Income Tax Expense 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net Income (43.3) (35.5) (35.0) (31.4) (64.4) (20.6) (20.6) (21.9) (17.4) (21.2) (14.4) (21.6) (12.2) (10.4) (11.8) (7.3) (7.3)
Per Share Data
EPS (Basic) -0.96 -0.84 -0.83 -0.90 -1.90 -0.61 -0.61 -0.65 -0.52 -0.63 -0.43 -0.64 -0.36 -0.31 -0.35 -5.76 -5.76
EPS (Diluted) -0.96 -0.84 -0.83 -0.90 -1.90 -0.61 -0.61 -0.65 -0.52 -0.63 -0.43 -0.64 -0.36 -0.31 -0.35 -5.76 -5.76
Shares Outstanding 45.1 38.5 41.9 35.0 33.9 33.6 33.6 33.5 33.5 33.5 33.5 33.5 33.5 33.5 33.5 1.3 1.3
Metric 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1 2024 Q4 2024 Q3 2024 Q2 2024 Q1 2023 Q4 2023 Q3 2023 Q2 2023 Q1 2022 Q4 2022 Q1
Current Assets
Cash & Cash Equivalents 62.1 45.5 112.7 112.8 49.9 74.3 282.9 298.7 317.4 150.4 141.4 157.8 0 163.4 0
Short-Term Investments 264.3 267.3 187.6 122.9 126.2 144.6 0 0 0 0 25 25 0 0 0
Net Receivables 0 0 0.5 0.5 0.5 0.5 0.5 0.8 0.9 0 0 0 0 0 0
Inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Current Assets 22.3 20.1 20.4 14.0 9.2 0 8.6 8.3 0 9.2 13.3 15.4 0 18.9 (37.3)
Total Current Assets 348.7 332.9 321.2 250.1 185.8 227.0 292.4 308.5 327.5 160.0 180.0 198.7 0 182.6 0
Non-Current Assets
Property, Plant & Equipment 0.4 0.0 0.0 0.1 0.1 0.2 0.2 0.2 0.2 0.3 0.0 0.1 0 0.1 0
Goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Intangible Assets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Long-Term Investments 0 0 5.1 18.8 29.4 47.7 0 0 0 0 0 0 0 0 0
Other Non-Current Assets 0.2 0.3 0.2 0.5 0.2 0.1 0.1 0.1 0.1 2.8 2.0 0.1 0 0.1 0
Total Non-Current Assets 0.6 0.3 5.3 19.4 29.7 48.0 0.3 0.3 0.4 3.1 2.0 0.2 0 0.2 0
Total Assets 349.3 333.2 326.6 269.5 215.5 274.9 292.7 308.9 327.8 163.1 182.0 198.8 0 182.8 0
Current Liabilities
Account Payables 8.7 5.9 5.9 4.1 4.4 3.8 4.6 3.8 4.1 4.5 4.8 6.5 0 3.1 0
Short-Term Debt 0.1 0.0 0.1 0 0 0 0.2 0 0 0 0 0 0 0 0
Deferred Revenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Current Liabilities 16.2 20.0 11.2 2.8 1.5 4.2 (0.1) 2.0 1.0 0 0 0 0 0 0
Total Current Liabilities 25.0 25.9 21.6 19.6 13.0 17.3 15.2 12.1 10.0 11.6 10.1 12.8 0 8.4 0
Non-Current Liabilities
Long-Term Debt 0.3 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Deferred Tax Liabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 (41.2)
Total Non-Current Liabilities 0.3 0 0 0 0 0.0 0.1 0.1 0.1 0.2 0 0 0 0.0 (41.2)
Total Liabilities 25.3 25.9 21.6 19.6 13.0 17.3 15.2 12.2 10.1 11.8 10.1 12.8 0 8.4 (41.2)
Stockholders' Equity
Common Stock 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 0.0 0.0 0 0 0
Retained Earnings (448.0) (404.6) (369.1) (334.1) (302.7) (238.3) (217.7) (197.1) (175.3) (157.8) (136.7) (122.3) 0 (88.5) 0
Accumulated Other Comprehensive Income (0.3) 0.0 0.2 (0.0) (0.0) (0.2) 0 0 0 0 (0.1) 0 0 0 (48.6)
Total Stockholders' Equity 324.0 307.2 305.0 249.9 202.5 257.7 277.5 296.7 317.7 151.3 171.9 186.0 0 174.5 41.2
Total Liabilities & Equity 349.3 333.2 326.6 269.5 215.5 274.9 292.7 308.9 327.8 163.1 182.0 198.8 0 182.8 0
Debt Metrics
Total Debt 0.4 0.0 0.1 0.1 0.1 0.2 0.4 0.2 0.3 0.3 0.0 0.1 0 0.1 0
Net Debt (61.7) (45.5) (112.6) (112.7) (49.7) (74.1) (282.5) (298.4) (317.1) (150.1) (141.3) (157.8) 0 (163.2) 0
Metric 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1 2024 Q4 2024 Q3 2024 Q2 2024 Q1 2023 Q4 2023 Q3 2023 Q2 2023 Q1 2022 Q4 2022 Q3 2022 Q2 2022 Q1
Operating Activities
Net Income (43.3) (35.5) (35.0) (31.4) (64.4) (20.6) (20.6) (21.9) (17.4) (21.2) (14.4) (21.6) (12.2) (10.4) (11.8) (7.3) (7.3)
Depreciation & Amortization 0 (3.0) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Stock-Based Compensation 0 3.2 3.7 3.3 2.3 1.0 0.9 0.8 0.6 0.3 0.2 0.2 0.2 0.1 0.1 0.1 0.1
Change in Working Capital (3.5) 4.7 (4.5) 2.0 (5.9) 3.5 3.4 2.0 (1.8) 6.0 (1.3) 12.8 (4.9) (5.6) (0.5) (2.0) (2.0)
Other Non-Cash Items 4.9 0 0 0 0 0 0 0 0 0 0 0 0 0 2.2 0.3 0.3
Operating Cash Flow (41.9) (30.7) (35.8) (26.1) (68.0) (16.2) (16.3) (19.1) (18.6) (14.9) (15.4) (8.6) (16.9) (15.9) (9.9) (8.9) (8.9)
Investing Activities
Capital Expenditure 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Acquisitions 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Purchases of Investments (64.4) (151.2) (90.4) (21.6) (9.8) (194.2) 0 0 0 0 0 (25) 0 0 0 0 0
Sales/Maturities of Investments 68.0 80.0 39.6 35.5 46.6 0 0 0 0 25 0 0 0 0 0 0 0
Other Investing Activities 0 0 0 0 0 1.7 0 0 0 0 0 0 0 0 0 0 0
Investing Cash Flow 3.6 (71.2) (50.8) 13.9 36.8 (192.5) 0 0 0 25 0 (25) 0 0 0 0 0
Financing Activities
Net Debt Issuance 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Stock Repurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Dividends Paid 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Financing Activities 0 (0.1) 0 (0.2) 0 0.1 0 0.0 0.0 0 0 0 0.0 0.0 0 30.0 30.0
Financing Cash Flow 54.9 34.7 86.5 75.1 6.8 0.1 0.5 0.4 185.6 (1.1) (1.0) (0.0) 45.0 109.7 0 30.0 30.0
Cash Position
Net Change in Cash 16.6 (67.1) (0.1) 62.9 (24.4) (208.6) (15.8) (18.7) 167.0 9.0 (16.5) 157.8 28.1 93.8 (9.9) 79.5 0
Cash at Beginning 45.5 112.7 112.8 49.9 74.3 282.9 298.7 317.4 150.4 141.4 157.8 0 163.4 69.5 79.5 0 0
Cash at End 62.1 45.5 112.7 112.8 49.9 74.3 282.9 298.7 317.4 150.4 141.4 157.8 191.5 163.4 69.5 79.5 0
Free Cash Flow (41.9) (30.7) (35.8) (26.1) (68.0) (16.2) (16.3) (19.1) (18.6) (14.9) (15.4) (8.6) (16.9) (15.9) (9.9) (8.9) (8.9)
Key Metrics 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1 2024 Q4 2024 Q3 2024 Q2 2024 Q1 2023 Q4 2023 Q3 2023 Q2 2023 Q1 2022 Q4 2022 Q3 2022 Q2 2022 Q1
Income Statement
Revenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Gross Profit 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Operating Income (46.1) (38.8) (38.3) (33.6) (66.8) (23.7) (24.2) (25.7) (20.7) (23.1) (16.7) (22.6) (12.2) (10.4) (11.8) (7.3) (7.3)
Net Income (43.3) (35.5) (35.0) (31.4) (64.4) (20.6) (20.6) (21.9) (17.4) (21.2) (14.4) (21.6) (12.2) (10.4) (11.8) (7.3) (7.3)
EPS (Diluted) -0.96 -0.84 -0.83 -0.90 -1.90 -0.61 -0.61 -0.65 -0.52 -0.63 -0.43 -0.64 -0.36 -0.31 -0.35 -5.76 -5.76
Balance Sheet
Cash & Equivalents 62.1 45.5 112.7 112.8 49.9 74.3 282.9 298.7 317.4 150.4 141.4 157.8 0 163.4 0
Total Assets 349.3 333.2 326.6 269.5 215.5 274.9 292.7 308.9 327.8 163.1 182.0 198.8 0 182.8 0
Total Debt 0.4 0.0 0.1 0.1 0.1 0.2 0.4 0.2 0.3 0.3 0.0 0.1 0 0.1 0
Stockholders' Equity 324.0 307.2 305.0 249.9 202.5 257.7 277.5 296.7 317.7 151.3 171.9 186.0 0 174.5 41.2
Cash Flow
Operating Cash Flow (41.9) (30.7) (35.8) (26.1) (68.0) (16.2) (16.3) (19.1) (18.6) (14.9) (15.4) (8.6) (16.9) (15.9) (9.9) (8.9) (8.9)
Capital Expenditure 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Free Cash Flow (41.9) (30.7) (35.8) (26.1) (68.0) (16.2) (16.3) (19.1) (18.6) (14.9) (15.4) (8.6) (16.9) (15.9) (9.9) (8.9) (8.9)